Literature DB >> 67886

Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus.

R G Olsen, E A Hoover, J P Schaller, L E Mathes, L H Wolff.   

Abstract

Four-week-old specific-pathogen-free cats were immunized with a combined vaccine composed of killed feline leukemia virus and killed feline oncornavirus-associated cell membrane antigen-containing tumor cells. Immunization induced feline oncornavirus-associated cell membrane antigen antibody titers ranging from 1:32 to 1:256 but did not elicit detectable virus-neutralizing antibody titers. Kittens immunized with tumor cells alone developed higher feline oncornavirus-associated cell membrane antigen antibody titers (ranging from 1:512 to 1:2048) than those given the combined vaccine. All kittens were challenged with virulent Dynder-Theilen feline sarcoma virus at 12 weeks of age. Seventy-five % of the kittens vaccinated with combined vaccine and 67% of unvaccinated control kittens developed progressive fibrosarcomas after challenge. By contrast, none of the kittens vaccinated with killed tumor cells alone developed progressive fibrosarcomas after challenge. The combined vaccine did not, however, inhibit the induction of feline leukemia virus viremia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 67886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II.

Authors:  C L Ruegg; C R Monell; M Strand
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

3.  Animal model of human disease: leukemic lymphoma.

Authors:  R G Olsen; L E Mathes; L C Hebebrand; E A Hoover; W S Nichols
Journal:  Am J Pathol       Date:  1980-03       Impact factor: 4.307

4.  Retrovirus sequences in a leukemic gibbon and its contact: evidence for partial provirus in the nonleukemic gibbon.

Authors:  F Wong-Staal; M S Reitz; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

5.  Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.

Authors:  N C Pedersen; L Johnson; D Birch; G H Theilen
Journal:  Vet Immunol Immunopathol       Date:  1986-02       Impact factor: 2.046

6.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Protection against feline leukemia by vaccination with a subunit vaccine.

Authors:  M G Lewis; L E Mathes; R G Olsen
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  The role of virus dose in experimental bovine leukemia virus infection in sheep.

Authors:  T Stirtzinger; V E Valli; J M Miller
Journal:  Can J Vet Res       Date:  1988-04       Impact factor: 1.310

9.  Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1.

Authors:  C L Ruegg; C R Monell; M Strand
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

10.  Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma.

Authors:  G Hunsmann; N C Pedersen; G H Theilen; H Bayer
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.